Vertex acquires Semma Therapeutics for $950M to develop diabetes cure
Category: #health  By Pankaj Singh  Date: 2019-09-05
  • share
  • Twitter
  • Facebook
  • LinkedIn

Vertex acquires Semma Therapeutics for $950M to develop diabetes cure
  • The acquisition for $950 million has been an all-cash deal.
     
  • The strategic acquisition is expected to align itself perfectly with Vertex’s aim to create revolutionary medicines.

Vertex Pharmaceuticals, a biopharmaceutical company based in Massachusetts, is acquiring Semma Therapeutics with its stem cell-based treatments for diabetes for $950 million which is slated to wind up in the fourth quarter.

Semma was founded by Douglas Melton, a Ph.D., in the year 2014 to work on a possible cure for Type 1 diabetes. The idea has been to turn the undifferentiated pluripotent stem cells into pancreatic beta cells that produce insulin and are capable of being transplanted into patients. The company later launched itself with an investment of $44 million in the Series A round along with a partnership with Novartis, that the company chose over other suitors focused on diabetes for its expertise in cell therapy.

Apparently, Semma raised a massive $114 million in the Series B round in 2017 as well as hired Bastiano Sanna as its CEO. Sanna had been Novartis’ global head of the programs associated with stem cell transplant. Vertex is currently counting on the treatment that is capable of replacing the daily injections along with chronic care that comprises as a treatment for people suffering from Type 1 diabetes.

Vertex’s CEO, Jeffery Leiden M.D., Ph.D., who is expected to pass on his position to Reshma Kewalramani, company Chief Medical Officer, next year in April, stated that the acquisition will align perfectly with the company’s strategy of making investments in scientific innovation that would create revolutionary medicines for people who are suffering from critical diseases in specialty markets.

Apparently, Semma has two-pronged approaches for treating diabetes. The first approach will require a direct transplant of pancreatic cells into the patient’s liver, so that will help in the production of insulin to control the levels of blood sugar. The second approach comprises a device which protects and delivers the transplanted cells from the immune system of the patient.

 

Source Credit- https://www.fiercebiotech.com/biotech/vertex-plunks-down-950m-for-stem-cell-player-semma-therapeutics



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

RADLogics obtains FDA's approval for AI-based chest X-Ray App
RADLogics obtains FDA's approval for AI-based chest X-Ray App
By Pankaj Singh

RADLogics Inc., a healthcare software company developing AI-powered solutions has reportedly received 510(k) clearance from the US FDA (Food and Drug Administration) for its latest AI-Powered chest X-ray pneumothorax a...

CDE of China NMPA clears I-Mab’s application for lemzoparlimab
CDE of China NMPA clears I-Mab’s application for lemzoparlimab
By Pankaj Singh

Clinical stage biopharmaceutical major, I-Mab, has reportedly announced that it has received the clearance of the Center for Drug Evaluation of the China National Medical Products Administration for its IND application...

Aoyuan Healthy to acquire 55% equity interest in Liantianmei
Aoyuan Healthy to acquire 55% equity interest in Liantianmei
By Pankaj Singh

Aoyuan Healthy Life Group Company Ltd., a renowned commercial property operation service and property management service provider based in China, has reportedly announced that Guangdong Xinyuerong Industrial Investment...